Related Experiment Videos
Adenoviral p53 gene therapy in head and neck squamous cell carcinoma cell lines
Yuzuru Higuchi1, Jun-Ichi Asaumi, Jun Murakami
1Department of Oral and Maxillofacial Radiology, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan.
Abstract:
We reconstructed the recombinant p53-expressing adenovirus and examined its infections and effects in head and neck squamous cell carcinoma cell lines. Eight human head and neck squamous cell carcinoma cell lines were infected by the recombinant adenovirus harboring the lacZ gene (AxCAiLacZ) or the wild-type p53 gene (AxCAip53), and the effects were investigated. The eight cell lines were successfully infected by AxCAiLacZ at a level of more than 50%. The survival of all 8 squamous cell lines were inhibited in the range from 8 to 26.7% by only one treatment of the AxCAip53 infection. This result suggested that p53 gene therapy might become a useful tool in head and neck squamous cell carcinoma treatment.
Insights
Recombinant adenovirus expressing p53 (AxCAip53) effectively infected head and neck squamous cell carcinoma cell lines. This p53 gene therapy demonstrated significant inhibition of cancer cell survival, suggesting its potential as a novel treatment.
Area of Science:
- Oncolytic virology
- Gene therapy
- Head and neck cancer research
Background:
- Head and neck squamous cell carcinoma (HNSCC) remains a significant clinical challenge.
- The tumor suppressor gene p53 plays a critical role in cell cycle regulation and apoptosis.
- Adenovirus vectors are widely used for gene delivery in cancer therapy.
Purpose of the Study:
- To construct and evaluate a recombinant adenovirus expressing wild-type p53 for HNSCC treatment.
- To assess the infectivity and anti-cancer effects of the p53-expressing adenovirus in HNSCC cell lines.
Main Methods:
- Recombinant adenoviruses, AxCAiLacZ (control) and AxCAip53 (p53-expressing), were constructed.
- Eight human HNSCC cell lines were infected with these adenoviruses.
- Infection efficiency and cell survival rates were measured.
Main Results:
- AxCAiLacZ successfully infected over 50% of the HNSCC cell lines.
- A single treatment with AxCAip53 inhibited the survival of all eight HNSCC cell lines by 8% to 26.7%.
- The p53-expressing adenovirus demonstrated significant oncolytic activity.
Conclusions:
- Recombinant p53-expressing adenovirus (AxCAip53) is an effective agent against HNSCC cell lines.
- p53 gene therapy holds promise as a potential therapeutic strategy for head and neck squamous cell carcinoma.
- Further investigation into p53 gene therapy for HNSCC is warranted.